Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
Sponsor: Ali Shamseddine
Listed as NCT03503630, this PHASE2 trial focuses on Locally Advanced Rectal Cancer and remains ongoing. Sponsored by Ali Shamseddine, it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ali Shamseddine
- Merck KGaA, Darmstadt, Germany
- Phoenix Clinical Research
For direct contact, visit the study record on ClinicalTrials.gov .